U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21NO2
Molecular Weight 307.387
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOXAVERINE

SMILES

CCc1cc2cc(c(cc2c(Cc3ccccc3)n1)OC)OC

InChI

InChIKey=MYCMTMIGRXJNSO-UHFFFAOYSA-N
InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C20H21NO2
Molecular Weight 307.387
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Moxaverine, a derivative of papaverine, is a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma. In addition, it has been studied in phase II of the clinical trial for the treatment of ischemia. This compound is prohibited by FEI (International Federation of equine).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion.
2004 Dec
Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma.
2005 Jun
Effect of systemic moxaverine on ocular blood flow in humans.
2009 Nov
Patents

Patents

Sample Use Guides

intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
Route of Administration: Intravenous
In Vitro Use Guide
Using a combination of techniques to assess quantitatively the shape and the filterability of red blood cells (RBC) after exposure to stress conditions (400 mosmol/l, lactacidosis, pH 6.8), the effects of 1-benzyl-3-ethyl-6,7-dimethoxy-isoquinoline hydrochloride (moxaverine-HCl, Kollateral) were tested. The shape of freely suspended RBC was quantified using the tangent count procedure. Moxaverine, when present in doses between 10(-5) und 10(-2) mol/l while the RBC are stressed, restored both the normal discoid red cell configuration and the microrheological performance when tested under low shear stresses. The data showed that moxaverine exerted protective effects on RBC membrane curvature and whole cell microrheological behavior (performance).
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:43:47 UTC 2021
Edited
by admin
on Sat Jun 26 07:43:47 UTC 2021
Record UNII
P3P08Y1XJ4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXAVERINE
INN   MI   WHO-DD  
INN  
Official Name English
MOXAVERINE [WHO-DD]
Common Name English
1-BENZYL-3-ETHYL-6,7-DIMETHOXYISOQUINOLINE
Systematic Name English
MOXAVERINE [MI]
Common Name English
MOXAVERINE [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QA03AD30
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
NCI_THESAURUS C29698
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
WHO-ATC A03AD30
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1853
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
MERCK INDEX
M7644
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C66209
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
RXCUI
52918
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
234-117-5
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
EPA CompTox
10539-19-2
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
PUBCHEM
70882
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
FDA UNII
P3P08Y1XJ4
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
CAS
10539-19-2
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL2105060
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
DRUG BANK
DB12251
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
MESH
C004490
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
EVMPD
SUB09082MIG
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
INN
4005
Created by admin on Sat Jun 26 07:43:47 UTC 2021 , Edited by admin on Sat Jun 26 07:43:47 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY